Navigation Links
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea

-- Primary endpoint achieved --

LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA (SWX:COPN) announced today positive preliminary results from its phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) in infectious diarrhoea. CB-01-11 is a broad spectrum, semi-synthetic antibiotic that is not absorbed when taken in tablet form. Through the use of Cosmo's MMX(tm) technology, which delivers the active ingredient into the colon, bacteria in the gastro intestinal tract that are important for vitamin synthesis are not sterilized. Given that it is practically not absorbed CB-01-11 is potentially applicable for the treatment of long term infections in the colon.

In the placebo controlled, randomized, double blind trial 120 patients in 8 sites in South Africa were treated with a 200mg tablet, 4 times per day for 3 days. The trial assessed non-inferiority versus Normix® (rifaximin) and the primary endpoint was the time from first ingestion of tablet to the last unformed stool. According to the preliminary reports CB-01-11 met this primary endpoint.

Mauro Ajani, CEO of Cosmo Pharmaceuticals, commented: "We are very encouraged about these preliminary results since many of the needs of patients are not adequately met with products currently on the market. Infections of the colon affect many more persons than colon inflammations and this is consequently a substantially larger market. We believe that our proprietary MMX(tm) technology will enable us to improve a range of products in colon infections and thus better meet patients' requirements."

Further analysis of the data is ongoing.

About Cosmo Pharmaceuticals

Cosmo is a speciality pharma company that aims to become a global leader in optimised therapies for certain gastrointestinal diseases. The com­pany's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulce
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting

Post Your Comments:
(Date:11/20/2009)... , BOSTON, Nov. 20 The Unite...pheld an earlier District Court ruling yesterday, ... Wholesale Price (AWP) pharmaceutical litigation a...Logo: http://www.newscom.com/cgi-bin/prnh/2008031...nt that awarded consumers who purchased the pharma...
(Date:11/20/2009)... , GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCal...nancial results for the fiscal fourth quarter and ...1, 2009. ,, The company will host a conference ...t 2:00 p.m. Eastern Time. Investors may access the...ted States and Canada), or 480-629-9835 (internati...
(Date:11/20/2009)... , NEW YORK, Nov. 20 Repor...eport is available in its catalogue. ,, Global...easing Adoption to Drive Growth ,, http://ww...-Blood-Glucose-Market-(SMBG )-Increasing-Adoption-..._medium=pr&utm_campaign=prnewswire ,, Des...
Breaking Medicine Technology:U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 2Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 3Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 4Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 5Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 6Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 7Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 8Orexigen 28R 29 Therapeutics Appoints Mark Booth Chief Commercial Officer 13661 1Orexigen 28R 29 Therapeutics Appoints Mark Booth Chief Commercial Officer 13661 2School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 1School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 2School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 3School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 4Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 1Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 4
... LINTHICUM, Md., April 27 Two studies presented a...can Urological Association (AUA) show that adult c...man immunodeficiency virus (HIV) and the risk of c...ng sexual dysfunction. , , The first study, by r...skin has the largest concentration of Langerhans, ...
... Final results from three large PEGINTRON(TM) clin...t of hepatitis C , , COPENHAGEN, Denmark, April 2...y reported that final results of three large PEGIN...address longstanding questions in the hepatitis C ... The results of the studies, involving a total of...
Other Medicine Technology:Adult Circumcision Reduces Risk of HIV Transmission Without Reducing Sexual Pleasure 2Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 9Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 10Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 11
(Date:11/20/2009)...as, TX, the new addition to blue sky scrubs will e...he USA. , Austin, TX (PRW...ependent medical scrubs brand which focuses primar...ution of hospital uniforms and surgical scrub hats... online boutique, the Austin, TX business has grow...
(Date:11/20/2009)...y supply, study finds , , FRIDAY, Nov. 2...of prescription drugs is up to one-third cheaper t...study. , U.S. researchers analyzed 26,852 presc...5, and found that patients who bought a three-mont...erage 29 percent in out-of-pocket costs. After the...
(Date:11/20/2009)...ted to continue, CDC says, , , FRIDAY, ...ed States are seeing declines in H1N1 swine flu ac... while the disease remains widespread in 43 states...k. , "We are beginning to see some declines in ...s still a lot of influenza everywhere," Dr. Anne S...
(Date:11/20/2009)...eased food insecurity as many face problem of hung...-- Project Bread, the state,s leading anti-hunger ...nnual status report on hunger in the Commonwealth....caused by high unemployment, point to 554,000 peop...d insecurity has found its way into middle class s...
(Date:11/20/2009)...0 Omnicell, Inc. (Nasdaq...o acute healthcare facilities, announced today the...ffray Healthcare Conference at the New York Palac... Randall A. Lipps, founder, chairman, president &..., Date: Tuesday, December 1, 2009 ,, Time:...
Breaking Medicine News(10 mins):Health News:Blue Sky Scrubs Secures a Second Texas Manufacturer 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4Health News:Omnicell to Present at Piper Jaffray Healthcare Conference 2
...ny as 200 people in every 100,000 in India suffer ...ed in the Indian State of Tamil Nadu for promoting...here public awareness with regard to the disease i...d 20 million people worldwide suffer strokes every...
... study has revealed that leisurely pursuits of peo... keeping Alzheimer's disease at bay. //The Columbi...europsychologist Yaakov Stern led the research stu... engaged in like just visiting friends, playing ca...
...eath of a 39-year-old man from Indonesia has been ...test conducted by a local health agency, according...med by World Health Organization recognized testin...ad chickens,' Hariadi Wibisono, the ministry's dir...
...ntomologist Cameron Currie of the University of Wi...used by the ants to protect their fungal garden fr...said that this discovery paved way to understand t...ch ants tended their fungal gardens. After the...
...more has been named America's fittest city by Men'... According to the ranking accorded by the Men's... Baltimore were Honolulu, Virginia Beach, Va., Tuc... was ranked as the 25th fittest city on a list of ...
...ealth sector was in full focus at the fourth Prava... Ministry of Overseas Indian Affairs and the Ameri...PI) reached an agreement to improve the primary he...tate for Overseas Indian Affairs Oscar Fernandes l...
Other Medicine News:Health News:Beneficial Symbiotic Relationship Between Ants And Bacteria. 2
Pipetman Large-Volume Kit
Phencyclidine - Rapid Test
Multi Drug Screen Tests - Rapid Test
Amphetamine - Rapid Test
Medicine Products: